search
Drug Discovery News
Trends
- 1Anthropic Launches Biology Lab in Ambition Beyond AI▼Anthropic's New Biology Lab Signals a Bigger Ambition Than Building AI
Anthropic has opened a new biology lab, a move widely read as a signal that the company's ambitions extend well beyond building artificial intelligence. The initiative suggests Anthropic wants to apply AI capabilities directly to biological research and drug discovery, positioning itself as a player in the life sciences rather than solely a model developer.
- 2
Anthropic has established its own wet laboratory as it expands its AI-driven drug discovery programme, according to Reuters. The lab will let the company test biological hypotheses generated by its AI models in real experiments. Observers see it as a notable step for an AI firm moving from software into hands-on biology and pharmaceutical research.
- 3AI helping scientists advance biological design in health research▼How AI is allowing scientists to advance biological design for health research: HealthLink
Scientists are increasingly using artificial intelligence to speed up biological design for health research, applying AI tools to engineer proteins, model biological systems and accelerate drug and therapy development. The approach is being highlighted as a way to cut research timelines and expand what laboratories can design, with health reporters examining how the technology is changing biomedical science and what it could mean for future treatments.
- 4Why regulatory screening comes after the recipe is done▼Why does regulatory screening happen after the recipe is done?
Drug Discovery News is examining why regulatory screening tends to occur only after a product's formulation, or 'recipe', has already been completed, rather than earlier in development. The question highlights a common tension in drug and food product development, where safety and compliance checks arrive late in the process, potentially forcing costly reformulations when problems are found.